L-4-Boronophenylalanine (L-BPA) is one of the two clinically approved drugs for boron neutron capture therapy of cancer. This mini-review describes various aspects of its chemistry: methods of synthesis, drug formulation, modifications directed to study its biodistribution and pharmacokinetics, as well as the application of L-BPA in organic synthesis.
Capture Therapy (BNCT) of cancer, a binary method for the treatment of cancer, which is based on the nuclear reaction of two essentially nontoxic species, nonradioactive 10 B and low-energy thermal neutrons. The neutron-capture reaction by 10 B produces an α-particle 4 He 2+ and 7 Li 3+ ion together with 2.4 MeV of kinetic energy and a 480 keV photon. These high-linear-energy transfer ions dissipate their kinetic energy before traveling one cell diameter (5-9 µm) in biological tissues, ensuring their potential for precise cell killing. Therefore, high accumulation and selective delivery of boron into the tumor tissue are the most important requirements to achieve efficient neutron capture therapy of cancer. In this review, various aspects of the chemistry of 4-boronophenylalanine will be considered, including methods of its synthesis, drug formulation, modifications directed to study its biodistribution and pharmacokinetics, as well as the application of L-BPA in organic synthesis.
Synthesis of 4-Boronophenylalanine
The growing significance of BPA as a BNCT agent as well as its synthetic utility in the preparation of 4-substituted phenylalanine derivatives resulted in a development of numerous methods of its synthesis based on different synthetic methods. At present, preparation of this rather simple compound can be considered as a striking illustration of the wealth and diversity of the arsenal of organic syntheses.
All described methods of synthesis of BPA could be divided into three groups depending on the bond formed in the key step of BPA synthesis.
Introduction of the amino acid group
The first group includes methods based on the formation of the C1-C2 bond between various synthetic equivalents of the amino acid and the boron-containing benzyl or benzaldehyde fragment.
This approach was used in the first synthesis of BPA by Snyder et al. 3 featuring the reaction of 4-dihydroxyborylbenzyl bromide with diethyl acetamidomalonate followed by alkaline hydrolysis and decarboxylation (Scheme 1). 
Scheme 2
The racemic mixture of L-and D-BPA can be separated by transformation of the amino acids into ethyl esters followed by selective hydrolysis of the L-isomer using the proteolytic enzyme chemotrypsin. 6 The same approach can be used for the enantioselective synthesis of L-BPA. One synthesis is based on an enantioselective alkylation of (2R)-(-)-2,5-dihydro-2-isopropyl-3,6-dimethoxypyrazine and gives L-BPA in 22% yield 7 (Scheme 3).
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Scheme 3
It should be noted that alkaline hydrolysis of the methyl ether at the last step results in some racemization of the amino acid. The racemization has been avoided by the enzymatic hydrolysis with chymotrypsin, however, the yield of this step drops to 64%. 7 Another enantioselective synthesis of L-BPA utilizes Seebach's imidazolidinone (Scheme 4). 
Scheme 4
Another effective approach makes use of p-formylboronic acid as the starting material. Protection of the dihydroxyboryl group with N-methyldiethanolamine 8 followed by the reaction of the formyl group with sodium salt of ethyl isocyanoacetate, catalytical hydrogenation of the double bond formed, and deprotection affords BPA in 52% yield (Scheme 5). 
Scheme 5
The other method based on p-formylboronic acid includes protection of the dihydroxyboryl function with 2,2-dimethylpropan-1,3-diol followed by the reaction with N-(benzyloxycarbonyl) phosphonoglycine trimethyl ester. The subsequent catalytic hydrogenation of the double bond and deprotection results in formation of BPA in 62% yield (Scheme 6). 10 
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Scheme 6
The enantioselective synthesis of L-BPA based on catalytic hydrogenation with the chiral catalyst (1,5-cyclooctadiene)[R-1,2-bis(diphenylphosphino)propane]rhodium(I) tetrafluoroborate has been proposed (Scheme 7). At present, only one example of this approach has been reported (Scheme 8). 12 Unfortunately, this synthesis requires the preliminary preparation of an L-alanine zinc derivative and gives a rather low yield of the target product (~40% based on 4-iodophenylboronic acid and ~25 % based on the amino acid). 
Introduction of boronic acid group into phenylalanine
The third group of methods of BPA synthesis is based on the introduction of the dihydroxyboryl substituent directly to the phenylalanine fragment with formation of the C-B bond. This approach allows using commercially available enantiomeric amino acids and minimizes transformations of the 10 B-enriched product. 
Scheme 9
The yield of the cross-coupling stage can be boosted up to 88% by protecting the carboxylic acid of the phenylalanine reactant as benzyl ester. 13 Another modification of this synthesis protects the carboxylic acid as methyl ester (Scheme 10). 
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Scheme 10
Further development of this approach utilizes the more readily available L-tyrosine triflate (instead of L-4-iodophenylalanine) and 1,3-diphenyl-1,3-propanediol ester of diboronic acid (instead of diboronic acid dipinacolate). 16 In the last case the yield of the target product is 48% (based on the amino acid) (Scheme 11). 
Scheme 11
The main disadvantages of these good-looking synthetic schemes are low-yields for the multi-step syntheses of the boronating agents 13, 16 and loss of more than 50% of 10 B-enriched materials at the coupling stage.
A breakthrough took place when the boronating agents were changed for pinacolborane, 17 which can be easily prepared by the reaction of commercially available borane-dimethylsulfide complex with pinacol. 18 Surprisingly, in this case the 4-iodo-L-phenylalanine derivatives have been found to be more effective than L-tyrosine triflates and nonaflates ( 
Scheme 12
The most recent improvement of this method employs ionic liquids [bmim] [X], (bmim = 1-butyl-3-methylimidazolium, X = BF 4 , PF 6 ) at the cross-coupling stage. The reaction was completed in 20 min producing the boronated phenylalanine in high yield (Scheme 13). The product is readily isolated by simple separation of phases. 
Scheme 13
In general, contemporary methods of organic synthesis allow synthesizing L-BPA with high efficiency. Some further improvement of the synthetic methods could be achieved by proper choice of the protective groups and deprotection reactions.
Drug Formulation and Delivery
Drug formulation and delivery is a very important factor, especially if a drug has poor solubility; this is the case for L-BPA having very limited water solubility (1.6 g/L). The crystal structure of L-BPA, established by X-ray diffraction method, shows an extended pattern of hydrogen bonding involving the boronic acid, carboxylate and ammonium groups. 21 The first attempt to solve the water solubility problem made use of the hydrochloride salt L-BPA·HCl. 22 However, the acidity of a 0.1 M solution has been reported with a pH ≈ 1.5.
A recent approach is based on tight and reversible esterification of the boronic acid moiety with 1,2-and 1,3-diols (Scheme 14). [23] [24] [25] The interaction between a boronic acid and a diol is known to be one of the strongest single-pair reversible functional group interactions in an aqueous environment and it is widely used for construction of boronic acid-based sugar sensors. 
Scheme 14
Therefore, it is not surprisingly that the formation of esters of L-BPA with monosaccharides (fructose, in particular) was proposed to produce a water soluble form of L-BPA for BNCT. [32] [33] [34] [35] [36] Intravenous injection of the L-BPA-fructose complex is now the standard method for its clinical use. According to multinuclear NMR spectroscopy data the L-BPAfructose complex in water buffered at physiological pH has been found to adopt the structure of β-D-fructofuranose 2,3,6-(p-phenylalanylorthoboronate). Another approach proposed to obtain water-soluble forms of BPA is the transformation into amides containing water-solubilizing hydroxyl groups. These forms have a high water solubility and lower cytotoxicity than BPA itself and might be suitable boron carriers on BNCT for malignant brain tumor. [38] [39] [40] 
Study of Biodistribution and Pharmacokinetics
Studying the biodistribution of pharmacokinetics of boron compounds (particularly BPA) is of great importance both for biomedical studies and for planning of patient treatment. Several methods have been developed to determine the boron content of biological research samples taken at biopsy and in tissues obtained from animal biodistribution experiments. These samples are often available in macroscopic quantities of 50-100 mg or more. Following the oxidative dissolution of weighed tissue samples, boron analysis of the aqueous sample is accomplished with inductively coupled plasma-or direct current plasma-atomic emission spectroscopy (ICP-AES and DCP-AES, respectively). These methods determine boron in tissue reliably at a level of 1 ppm. 41 However, none of these methods can be applied non-invasively for monitoring the in situ boron distribution in patients. For in vivo imaging of boron compounds, radio-labeled derivatives are of particular interest because their biodistribution can be easily monitored. In many cases, radio-labeling provides detailed information about boron pharmacokinetics that can be used to generate improved patient treatment protocols, for example, by providing information about the required dosage of tumorseeking boron conjugates, and optimal treatment time. Positron emission tomography (PET) using 18 F-labeled L-BPA (Scheme 15) 42 has been developed for this purpose and at present is widely used for patient treatment. B magnetic resonance imaging (MRI) was proposed as a non-invasive method for the in vivo assessment of BNCT agents, but its practical utilization still remains to be proven. 50, 51 The other recently developed approach is 19 F MRI of fluorine-containing BPA derivatives. 52 
Non-medical Applications -BPA in Organic Synthesis
Development of effective methods of BPA synthesis resulted in active use of this amino acid and its derivatives in organic synthesis utilizing Pd-catalyzed cross-coupling (Suzuki-Miyaura reaction). This approach was applied to the synthesis of 4 ) derivatives of phenylalanine. Very recently this methodology was used for the introduction of the L-phenylalanine moiety into purine bases, nucleosides and nucleotides. 57, 58 Other examples are the Pd-catalyzed synthesis of L-phenylalanine-based amidine 59 and the Cumediated reaction with phenols.
14 Some examples are shown below. 
Conclusions
Contemporary methods of organic synthesis open ways to the synthesis of L-BPA with high efficiency. Some further improvement of the developed synthetic methods could be achieved by proper choice of the protective groups and deprotection reactions. At present, good availability of L-BPA allows its use in organic synthesis for the preparation of various substituted phenylalanines.
Presently, BPA is the most studied boron-containing amino acid; however, it should be remembered that progress of BNCT caused the synthesis of a wide arsenal of boronated amino acids; 60 probably, some of these compounds or their analogues could soon find an application as BNCT drugs.
